查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2085298

伴隨診斷市場：2026-2032年全球市場預測（按交付方式、技術、檢體類型、生物標記分類、應用、最終用戶和分銷管道分類）

Companion Diagnostics Market by Offering, Technology, Sample Type, Biomarker Class, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，伴隨診斷市場將成長至 184.8 億美元，複合年成長率為 10.99%。

主要市場統計數據
基準年 2025 89億美元
預計年份：2026年 98.4億美元
預測年份 2032 184.8億美元
複合年成長率 (%) 10.99%

伴隨診斷（CDx）透過檢驗的診斷測試與特定療法的安全有效應用相結合，已成為精準醫療的核心運作模式。在腫瘤學、罕見病學、感染疾病和免疫學領域，伴隨診斷能夠幫助臨床醫生識別最有可能從標靶治療中獲益的患者，避免無效治療，並為基於循證醫學的保險報銷決策提供支持。

這一趨勢的促進因素包括全球癌症負擔的日益加重、次世代定序（NGS）技術的廣泛應用、生物標記標標靶治療法規核准的不斷增加，以及EGFR、ALK、BRAF、HER2、BRCA1/2、PD-L1、MSI、NTRK和KRAS等生物標記臨床應用的不斷擴展。隨著藥物研發越來越主導生物標記，製藥公司、診斷公司、實驗室和醫療保健系統正在加強合作，以整合臨床檢驗、監管策略、指南採納和真實世界數據（REW）的生成。

伴隨診斷領域的變革性變化

伴隨診斷領域正從單分析物檢測轉向多重檢測和基於新一代定序（NGS）的平台，這些平台能夠從有限的組織或血液樣本中評估多種具有治療應用價值的生物標記。這種轉變將加快治療方案的選擇，提高切片檢查材料的有效利用，並進一步契合現代腫瘤治療路徑，該路徑針對單一腫瘤類型提供多種標靶治療選擇。

人工智慧對伴隨診斷的累積影響

人工智慧正在透過改進突變解讀、數位病理工作流程、放射組學、檢查室自動化、品管和臨床試驗匹配，對伴隨診斷產生影響。經過適當檢驗後，人工智慧驅動的工具可以幫助確定基因組突變的優先順序、檢測病理影像中的模式、輔助生物標記的發現，並整合來自真實世界資料集的證據。

關於伴隨診斷的關鍵區域見解

由於美國食品藥物管理局（FDA）健全的監管流程、高度集中的生物製藥創新、廣泛的分子檢測基礎設施以及標靶癌症療法的快速發展，北美仍然是伴隨診斷領域的領先地區。美國透過廣泛的臨床試驗活動、納入國家指南以及完善的檢查室自建檢測（LDT）和體外診斷（IVD）生態系統，推動該地區的發展。同時，加拿大也受惠於其公共衛生技術評估流程、省級癌症計畫以及不斷擴展的精準醫療舉措。

全球伴隨診斷市場關鍵群洞察

歐盟是伴隨診斷的關鍵區域。這是因為體外診斷醫療設備法規 (IVDR) 加強了對臨床證據、性能評估和認證機構監管的要求，要求製造商提交更嚴格的資料包，並加強上市後監管。七國集團 (G7) 擁有成熟的醫保報銷體系、深厚的學術研究基礎、腫瘤學指南的採納以及支持將伴隨診斷早期整合到治療研發中的藥物開發平臺。同時，北約成員國受益於先進的醫療基礎設施、優先保障的資料安全共享以及跨境臨床研究網路。

主要國家伴隨診斷採用趨勢

美國憑藉其經FDA批准的伴隨診斷（CDx）核准途徑、完善的腫瘤學指南、積極的生物醫學研發以及NGS檢測板的廣泛應用，在伴隨診斷的商業化方面處於領先地位。加拿大則強調透過省級醫療保健系統和衛生技術評估（HTA）進行循證應用，而墨西哥和巴西則透過私人腫瘤網路、參考實驗室以及對標靶治療日益成長的需求來擴大伴隨診斷的可及性。

為伴隨診斷產業的領導者提供實用建議。

產業領導者應從臨床開發的早期階段就將伴隨診斷試劑的開發與治療藥物的開發相結合，確保將生物標記策略、檢測設計、檢體管理和監管要求整合到試驗方案中。聯合開發可以降低核准風險，並提高在治療藥物進入臨床應用階段時，診斷試劑能夠同時可用的可能性。

伴隨診斷分析的調查方法

本執行摘要採用二手研究框架編寫，整合了監管機構、臨床指南、同行評審的生物醫學文獻、衛生技術評估機構、公共衛生組織和權威科學資訊來源發布的資訊。一手資訊來源通常包括美國食品藥物管理局（FDA）、歐盟委員會、各國衛生組織、世界衛生組織（WHO）、國際癌症研究機構（IARC）、腫瘤指南制定機構以及關於分子診斷、生物標記檢測和標靶治療的科學出版物。

結論：伴隨診斷是精準醫療的成長引擎

伴隨診斷不再是藥物研發中的輔助工具，而是精準醫療的基石。隨著治療方案越來越注重生物標記特異性，提供準確、及時且經臨床檢驗的診斷結果的能力，對於決定患者的就醫途徑、治療方案以及醫療保健的價值將變得日益重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 伴隨診斷市場：依產品/服務分類

  • 裝置
    • 檢體預處理系統
    • 放大和檢測裝置
    • 定序儀和讀取器
  • 試劑和耗材
    • 檢測試劑組
    • 引子、探針、寡核苷酸
    • 抗體和染色試劑
  • 軟體與生物資訊學
    • 原始資料處理
    • 變異調用和註釋
    • 臨床解讀與報告
  • 服務
    • 檢測方法開發與驗證
    • 臨床試驗測試
    • 監管和合規支持
    • 支持數據分析和真實世界證據（RWE）

第8章：伴隨診斷市場：依技術分類

  • 免疫檢測技術
    • 免疫組織化學
    • ELISA
  • 原位雜合反應
  • 次世代定序
    • 標靶定序
    • 轉錄定序
    • 全基因測序
  • 聚合酵素鏈鎖反應（PCR）
    • 數位PCR
    • 即時PCR
  • 微陣列技術

第9章：伴隨診斷市場：依樣本類型分類

  • 組織
  • 血
  • 尿
  • 唾液

第10章：伴隨診斷市場：依生物標記類型分類

  • 分子和基因生物標記
  • 蛋白質生物標記
  • 藥物基因學標記
  • 動態標記物

第11章 伴隨診斷市場：依應用領域分類

  • 自體免疫/發炎性疾病
  • 感染疾病
  • 腫瘤學
    • 非小細胞肺癌（NSCLC）
    • 乳癌
    • 結腸癌
    • 黑色素瘤
    • 骨髓惡性腫瘤
  • 神經病學
  • 內分泌學

第12章 伴隨診斷市場：依最終使用者分類

  • 學術和研究機構
  • 診斷檢查室
  • 醫院
  • 製藥和生物技術公司

第13章：伴隨診斷市場：依通路分類

  • 直銷
  • 分銷商銷售額
  • 線上銷售

第14章 伴隨診斷市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第15章：伴隨診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 伴隨診斷市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第18章：公司簡介

  • F. Hoffmann-La Roche AG
  • Abbott Laboratories
  • Danaher Corporation
  • Thermo Fisher Scientific Inc.
  • QIAGEN NV
  • Illumina, Inc.
  • Agilent Technologies, Inc.
  • Myriad Genetics, Inc.
  • Becton, Dickinson and Company
  • bioMerieux SA
  • Guardant Health, Inc
  • ARUP Laboratories
  • Caris Life Sciences
  • Almac Group Limited
  • Siemens Healthineers AG
  • Sanofi SA
  • Laboratory Corporation of America Holdings
  • Bio-Rad Laboratories, Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Quest Diagnostics Incorporated
  • Abnova Corporation
  • Agendia, Inc.
  • Amoy Diagnostics Co., Ltd.
  • Bio-Techne Corporation
  • Eli Lilly and Company
  • ICON PLC
  • Invivoscribe, Inc.
  • NeoGenomics, Inc.
  • PathAI, Inc.
  • R-Biopharm AG
  • Sysmex Corporation
  • Tempus AI, Inc.
Product Code: MRR-433AB1DC2871

The Companion Diagnostics Market is projected to grow by USD 18.48 billion at a CAGR of 10.99% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.90 billion
Estimated Year [2026] USD 9.84 billion
Forecast Year [2032] USD 18.48 billion
CAGR (%) 10.99%

Companion diagnostics (CDx) have become a central operating model for precision medicine, linking a validated diagnostic test to the safe and effective use of a specific therapy. In oncology, rare disease, infectious disease, and immunology, CDx enables clinicians to identify patients most likely to benefit from targeted treatment, avoid ineffective therapies, and support evidence-based reimbursement decisions.

Momentum is reinforced by the rising global cancer burden, broader adoption of next-generation sequencing (NGS), increasing regulatory approvals for biomarker-linked targeted therapies, and expanding clinical use of biomarkers such as EGFR, ALK, BRAF, HER2, BRCA1/2, PD-L1, MSI, NTRK, and KRAS. As drug development becomes more biomarker-led, pharmaceutical sponsors, diagnostic developers, laboratories, and health systems are aligning around integrated clinical validation, regulatory strategy, guideline adoption, and real-world evidence generation.

Transformative Shifts in the Companion Diagnostics Landscape

The companion diagnostics landscape is shifting from single-analyte testing toward multiplex and NGS-based platforms that can evaluate multiple actionable biomarkers from limited tissue or blood samples. This shift supports faster treatment selection, better use of biopsy material, and stronger alignment with modern oncology pathways where several targeted therapy options may be available for one tumor type.

Regulatory and reimbursement expectations are also transforming the sector. Agencies including the U.S. FDA require strong analytical and clinical validation for CDx claims, while payers increasingly assess clinical utility, guideline inclusion, and health-economic value. Liquid biopsy, decentralized testing networks, tumor-agnostic biomarkers, and standardized laboratory quality systems are further changing how precision medicine is delivered across community and academic care settings.

Cumulative Impact of Artificial Intelligence on Companion Diagnostics

Artificial intelligence is influencing companion diagnostics by improving variant interpretation, digital pathology workflows, radiomics, laboratory automation, quality control, and clinical trial matching. AI-enabled tools can help prioritize genomic alterations, detect patterns in pathology images, support biomarker discovery, and synthesize evidence from real-world datasets when appropriately validated.

The cumulative impact of AI is expected to be strongest where it reduces turnaround time, improves reproducibility, and connects multi-omic data with therapy selection. However, adoption depends on transparent validation, representative training datasets, cybersecurity, explainability, clinical workflow integration, and compliance with medical device regulations, HIPAA, GDPR, and emerging AI governance frameworks such as the European Union AI Act.

Key Regional Insights for Companion Diagnostics

North America remains a leading region for companion diagnostics due to strong FDA regulatory pathways, a high concentration of biopharmaceutical innovation, broad molecular testing infrastructure, and rapid adoption of targeted oncology therapies. The United States anchors regional progress through extensive clinical trial activity, national guideline integration, and established laboratory-developed test and in vitro diagnostic ecosystems, while Canada benefits from public health technology assessment processes, provincial oncology programs, and expanding precision medicine initiatives.

Europe is shaped by the In Vitro Diagnostic Regulation, GDPR, national reimbursement systems, and strong translational research networks across Germany, France, Italy, Spain, and the United Kingdom. Asia-Pacific is expanding as China, Japan, South Korea, India, Australia, and ASEAN countries invest in cancer genomics, domestic diagnostic manufacturing, clinical trial capacity, and precision medicine access. Latin America is progressing through private-sector molecular diagnostics adoption and oncology modernization in Brazil and Mexico, while the Middle East is advancing through tertiary care centers, national genomics initiatives, and investment in advanced cancer care. Africa is developing more gradually, supported by regional reference laboratories, public health collaborations, and growing demand for molecular oncology diagnostics in major urban centers.

Key Group Insights Across Global Companion Diagnostics Markets

The European Union is a pivotal group for companion diagnostics because IVDR has increased requirements for clinical evidence, performance evaluation, and notified body oversight, pushing manufacturers toward more rigorous data packages and stronger post-market surveillance. G7 markets provide mature reimbursement frameworks, academic research depth, oncology guideline adoption, and drug development pipelines that support early CDx integration into therapeutic development, while NATO countries benefit from advanced healthcare infrastructure, secure data collaboration priorities, and cross-border clinical research networks.

BRICS countries are increasingly important because of large patient populations, expanding oncology treatment access, and government support for genomics and local diagnostic capacity, particularly in China, India, and Brazil, with Russia and South Africa contributing through regional laboratory infrastructure and evolving precision oncology programs. ASEAN markets are gaining relevance as Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines expand laboratory networks and oncology services, though reimbursement and infrastructure remain uneven. GCC countries are investing in precision medicine, genomic screening, and advanced cancer centers, positioning the group as a high-potential environment for premium molecular diagnostics and oncology-linked CDx adoption.

Key Country Insights for Companion Diagnostics Adoption

The United States leads in companion diagnostics commercialization through FDA-approved CDx pathways, strong oncology guidelines, high biomedical R&D activity, and widespread use of NGS panels. Canada emphasizes evidence-based adoption through provincial health systems and health technology assessment, while Mexico and Brazil are expanding access through private oncology networks, reference laboratories, and growing demand for targeted therapies.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine advanced oncology care with national reimbursement decision-making, molecular tumor boards, and IVDR-aligned diagnostic standards, while Russia's environment is shaped by local healthcare funding, domestic diagnostic capacity, and access considerations. China is scaling precision oncology through local innovation, hospital-based testing, and large clinical datasets; India is growing through cost-sensitive molecular testing and urban cancer centers; Japan and South Korea benefit from strong regulatory systems, high clinical adoption of advanced diagnostics, and precision oncology programs; and Australia supports adoption through public reimbursement mechanisms, national cancer genomics initiatives, and specialist pathology networks.

Actionable Recommendations for Companion Diagnostics Industry Leaders

Industry leaders should align CDx development with therapeutic development from the earliest clinical phases, ensuring biomarker strategy, assay design, sample logistics, and regulatory requirements are built into trial protocols. Co-development reduces approval risk and improves the probability that a diagnostic will be available when the therapy reaches clinical use.

Organizations should prioritize scalable NGS and liquid biopsy platforms, invest in real-world evidence, and build reimbursement dossiers that demonstrate clinical utility, analytical validity, and cost effectiveness. Strategic partnerships among drug developers, diagnostic manufacturers, reference laboratories, hospitals, academic centers, and digital health providers will be essential for faster turnaround time, equitable access, quality assurance, and broader precision medicine adoption.

Research Methodology for Companion Diagnostics Analysis

This executive summary is developed using a secondary research framework that synthesizes publicly available information from regulatory agencies, clinical guidelines, peer-reviewed biomedical literature, health technology assessment bodies, public health organizations, and recognized scientific sources. Key sources typically include the U.S. FDA, European Commission, national health agencies, WHO, IARC, oncology guideline bodies, and scientific publications covering molecular diagnostics, biomarker testing, and targeted therapy.

The methodology emphasizes triangulation across regulatory approvals, biomarker-linked therapy trends, diagnostic platform adoption, regional healthcare infrastructure, reimbursement dynamics, and technology developments. Insights are validated against observable signals such as CDx approvals, precision oncology programs, NGS utilization, AI governance developments, laboratory quality standards, and expanding clinical use of tissue and liquid biopsy testing.

Conclusion: Companion Diagnostics as a Precision Medicine Growth Engine

Companion diagnostics are no longer a specialized adjunct to drug development; they are a foundational component of precision medicine. As therapies become more biomarker-specific, the ability to deliver accurate, timely, and clinically validated diagnostic results will increasingly determine patient access, treatment selection, and healthcare value.

The sector's evolution is supported by targeted therapy pipelines, expanding NGS adoption, liquid biopsy innovation, AI-enabled interpretation, and global investment in oncology infrastructure. Organizations that integrate regulatory excellence, evidence generation, reimbursement strategy, data governance, and laboratory scalability will be best positioned to lead the next phase of companion diagnostics advancement.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Companion Diagnostics Market, by Offering

  • 7.1. Instrumentation
    • 7.1.1. Sample Preparation Systems
    • 7.1.2. Amplification & Detection Instruments
    • 7.1.3. Sequencers & Readers
  • 7.2. Reagents & Consumables
    • 7.2.1. Assay Reagent Kits
    • 7.2.2. Primers Probes & Oligonucleotides
    • 7.2.3. Antibodies & Staining Reagents
  • 7.3. Software & Bioinformatics
    • 7.3.1. Primary Data Processing
    • 7.3.2. Variant Calling & Annotation
    • 7.3.3. Clinical Interpretation & Reporting
  • 7.4. Services
    • 7.4.1. Assay Development & Validation
    • 7.4.2. Clinical Trial Testing
    • 7.4.3. Regulatory & Compliance Support
    • 7.4.4. Data Analytics & Real-World Evidence Support

8. Companion Diagnostics Market, by Technology

  • 8.1. Immunoassay Technologies
    • 8.1.1. Immunohistochemistry
    • 8.1.2. ELISA
  • 8.2. In Situ Hybridization
  • 8.3. Next Generation Sequencing
    • 8.3.1. Targeted Sequencing
    • 8.3.2. Transcriptome Sequencing
    • 8.3.3. Whole Genome Sequencing
  • 8.4. Polymerase Chain Reaction (PCR)
    • 8.4.1. Digital PCR
    • 8.4.2. Real time PCR
  • 8.5. Microarray Technologies

9. Companion Diagnostics Market, by Sample Type

  • 9.1. Tissue
  • 9.2. Blood
  • 9.3. Urine
  • 9.4. Saliva

10. Companion Diagnostics Market, by Biomarker Class

  • 10.1. Molecular/Genomic Biomarkers
  • 10.2. Protein Biomarkers
  • 10.3. Pharmacogenetic Markers
  • 10.4. Pharmacodynamic Markers

11. Companion Diagnostics Market, by Application

  • 11.1. Autoimmune & Inflammatory Diseases
  • 11.2. Infectious Diseases
  • 11.3. Oncology
    • 11.3.1. Non-Small Cell Lung Cancer (NSCLC)
    • 11.3.2. Breast Cancer
    • 11.3.3. Colorectal Cancer
    • 11.3.4. Melanoma
    • 11.3.5. Hematologic Malignancies
  • 11.4. Neurology
  • 11.5. Endocrinology

12. Companion Diagnostics Market, by End User

  • 12.1. Academic & Research Organizations
  • 12.2. Diagnostic Laboratories
  • 12.3. Hospitals
  • 12.4. Pharmaceutical & Biotechnology Companies

13. Companion Diagnostics Market, by Distribution Channel

  • 13.1. Direct Sales
  • 13.2. Distributor Sales
  • 13.3. Online Sales

14. Companion Diagnostics Market, by Region

  • 14.1. Asia-Pacific
  • 14.2. North America
  • 14.3. Latin America
  • 14.4. Europe
  • 14.5. Middle East
  • 14.6. Africa

15. Companion Diagnostics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Companion Diagnostics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. F. Hoffmann-La Roche AG
  • 18.2. Abbott Laboratories
  • 18.3. Danaher Corporation
  • 18.4. Thermo Fisher Scientific Inc.
  • 18.5. QIAGEN N.V.
  • 18.6. Illumina, Inc.
  • 18.7. Agilent Technologies, Inc.
  • 18.8. Myriad Genetics, Inc.
  • 18.9. Becton, Dickinson and Company
  • 18.10. bioMerieux SA
  • 18.11. Guardant Health, Inc
  • 18.12. ARUP Laboratories
  • 18.13. Caris Life Sciences
  • 18.14. Almac Group Limited
  • 18.15. Siemens Healthineers AG
  • 18.16. Sanofi S.A.
  • 18.17. Laboratory Corporation of America Holdings
  • 18.18. Bio-Rad Laboratories, Inc.
  • 18.19. Merck & Co., Inc.
  • 18.20. Pfizer Inc.
  • 18.21. Quest Diagnostics Incorporated
  • 18.22. Abnova Corporation
  • 18.23. Agendia, Inc.
  • 18.24. Amoy Diagnostics Co., Ltd.
  • 18.25. Bio-Techne Corporation
  • 18.26. Eli Lilly and Company
  • 18.27. ICON PLC
  • 18.28. Invivoscribe, Inc.
  • 18.29. NeoGenomics, Inc.
  • 18.30. PathAI, Inc.
  • 18.31. R-Biopharm AG
  • 18.32. Sysmex Corporation
  • 18.33. Tempus AI, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL COMPANION DIAGNOSTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL COMPANION DIAGNOSTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL COMPANION DIAGNOSTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL COMPANION DIAGNOSTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL COMPANION DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL COMPANION DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY OFFERING, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY OFFERING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY BIOMARKER CLASS, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY BIOMARKER CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INSTRUMENTATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INSTRUMENTATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INSTRUMENTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SAMPLE PREPARATION SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SAMPLE PREPARATION SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SAMPLE PREPARATION SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL AMPLIFICATION & DETECTION INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL AMPLIFICATION & DETECTION INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL AMPLIFICATION & DETECTION INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SEQUENCERS & READERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SEQUENCERS & READERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SEQUENCERS & READERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL REAGENTS & CONSUMABLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL REAGENTS & CONSUMABLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL REAGENTS & CONSUMABLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ASSAY REAGENT KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ASSAY REAGENT KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ASSAY REAGENT KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PRIMERS PROBES & OLIGONUCLEOTIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PRIMERS PROBES & OLIGONUCLEOTIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PRIMERS PROBES & OLIGONUCLEOTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTIBODIES & STAINING REAGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTIBODIES & STAINING REAGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTIBODIES & STAINING REAGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SOFTWARE & BIOINFORMATICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SOFTWARE & BIOINFORMATICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SOFTWARE & BIOINFORMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PRIMARY DATA PROCESSING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PRIMARY DATA PROCESSING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PRIMARY DATA PROCESSING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL VARIANT CALLING & ANNOTATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VARIANT CALLING & ANNOTATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VARIANT CALLING & ANNOTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CLINICAL INTERPRETATION & REPORTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CLINICAL INTERPRETATION & REPORTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CLINICAL INTERPRETATION & REPORTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ASSAY DEVELOPMENT & VALIDATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ASSAY DEVELOPMENT & VALIDATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ASSAY DEVELOPMENT & VALIDATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CLINICAL TRIAL TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CLINICAL TRIAL TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CLINICAL TRIAL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL REGULATORY & COMPLIANCE SUPPORT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL REGULATORY & COMPLIANCE SUPPORT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL REGULATORY & COMPLIANCE SUPPORT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DATA ANALYTICS & REAL-WORLD EVIDENCE SUPPORT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DATA ANALYTICS & REAL-WORLD EVIDENCE SUPPORT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DATA ANALYTICS & REAL-WORLD EVIDENCE SUPPORT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IMMUNOASSAY TECHNOLOGIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IMMUNOASSAY TECHNOLOGIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL IMMUNOASSAY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ELISA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ELISA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ELISA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL IN SITU HYBRIDIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL IN SITU HYBRIDIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL IN SITU HYBRIDIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL TRANSCRIPTOME SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL TRANSCRIPTOME SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL TRANSCRIPTOME SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL POLYMERASE CHAIN REACTION (PCR) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL POLYMERASE CHAIN REACTION (PCR) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL POLYMERASE CHAIN REACTION (PCR) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DIGITAL PCR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DIGITAL PCR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL DIGITAL PCR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL REAL TIME PCR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL REAL TIME PCR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL REAL TIME PCR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL MICROARRAY TECHNOLOGIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL MICROARRAY TECHNOLOGIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL MICROARRAY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL TISSUE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL TISSUE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL TISSUE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BLOOD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BLOOD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BLOOD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL URINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL URINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL URINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL SALIVA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL SALIVA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL SALIVA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY BIOMARKER CLASS, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL MOLECULAR/GENOMIC BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL MOLECULAR/GENOMIC BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL MOLECULAR/GENOMIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL PROTEIN BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL PROTEIN BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PROTEIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL PHARMACOGENETIC MARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL PHARMACOGENETIC MARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL PHARMACOGENETIC MARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL PHARMACODYNAMIC MARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL PHARMACODYNAMIC MARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL PHARMACODYNAMIC MARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL AUTOIMMUNE & INFLAMMATORY DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL AUTOIMMUNE & INFLAMMATORY DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL AUTOIMMUNE & INFLAMMATORY DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL NON-SMALL CELL LUNG CANCER (NSCLC) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL NON-SMALL CELL LUNG CANCER (NSCLC) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL NON-SMALL CELL LUNG CANCER (NSCLC) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL COLORECTAL CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL COLORECTAL CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL COLORECTAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL MELANOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL MELANOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL MELANOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL NEUROLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL NEUROLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL NEUROLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL ENDOCRINOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL ENDOCRINOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL ENDOCRINOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL ACADEMIC & RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL ACADEMIC & RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL ACADEMIC & RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL DIRECT SALES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL DIRECT SALES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL DIRECT SALES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL DISTRIBUTOR SALES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL DISTRIBUTOR SALES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL DISTRIBUTOR SALES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL ONLINE SALES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL ONLINE SALES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL ONLINE SALES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY INSTRUMENTATION, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY SOFTWARE & BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY BIOMARKER CLASS, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY INSTRUMENTATION, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY SOFTWARE & BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 198. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY BIOMARKER CLASS, 2018-2032 (USD MILLION)
  • TABLE 200. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 202. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY INSTRUMENTATION, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY SOFTWARE & BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 210. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 212. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 214. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY BIOMARKER CLASS, 2018-2032 (USD MILLION)
  • TABLE 216. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 218. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY INSTRUMENTATION, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY SOFTWARE & BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY BIOMARKER CLASS, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 236. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 238. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY INSTRUMENTATION, 2018-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 240. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY SOFTWARE & BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 242. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 244. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 246. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY BIOMARKER CLASS, 2018-2032 (USD MILLION)
  • TABLE 248. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 250. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 252. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 253. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 254. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY INSTRUMENTATION, 2018-2032 (USD MILLION)
  • TABLE 255. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 256. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY SOFTWARE & BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 257. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 258. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 259. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 260. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 261. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 262. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY BIOMARKER CLASS, 2018-2032 (USD MILLION)
  • TABLE 264. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 265. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 266. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 267. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 268. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 269. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 270. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 271. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY INSTRUMENTATION, 2018-2032 (USD MILLION)
  • TABLE 272. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 273. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY SOFTWARE & BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 274. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 275. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 276. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 277. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 278. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 279. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY BIOMARKER CLASS, 2018-2032 (USD MILLION)
  • TABLE 281. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 282. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 283. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 284. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 285. GCC COMPANION DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 286. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 287. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY INSTRUMENTATION, 2018-2032 (USD MILLION)
  • TABLE 288. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 289. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY SOFTWARE & BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 290. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 291. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 292. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 293. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 294. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 295. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY BIOMARKER CLASS, 2018-2032 (USD MILLION)
  • TABLE 297. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 298. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 299. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 300. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 301. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 302. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 303. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY INSTRUMENTATION, 2018-2032 (USD MILLION)
  • TABLE 304. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 305. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY SOFTWARE & BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 306. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 307. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 308. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 309. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 310. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 311. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 312. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY BIOMARKER CLASS, 2018-2032 (USD MILLION)
  • TABLE 313. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 314. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 315. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 316. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 317. BRICS COMPANION DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 318. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 319. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY INSTRUMENTATION, 2018-2032 (USD MILLION)
  • TABLE 320. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 321. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY SOFTWARE & BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 322. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 323. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 324. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 325. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 326. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 327. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 328. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY BIOMARKER CLASS, 2018-2032 (USD MILLION)
  • TABLE 329. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 330. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 331. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 332. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 333. G7 COMPANION DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 334. G7 COMPANION DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 335. G7 COMPANION DIAGNOSTICS MARKET SIZE, BY INSTRUMENTATION, 2018-2032 (USD MILLION)
  • TABLE 336. G7 COMPANION DIAGNOSTICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 337. G7 COMPANION DIAGNOSTICS MARKET SIZE, BY SOFTWARE & BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 338. G7 COMPANION DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 339. G7 COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 340. G7 COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 341. G7 COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 342. G7 COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 343. G7 COMPANION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 344. G7 COMPANION DIAGNOSTICS MARKET SIZE, BY BIOMARKER CLASS, 2018-2032 (USD MILLION)
  • TABLE 345. G7 COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 346. G7 COMPANION DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 347. G7 COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 348. G7 COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 349. NATO COMPANION DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 350. NATO COMPANION DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 351. NATO COMPANION DIAGNOSTICS MARKET SIZE, BY INSTRUMENTATION, 2018-2032 (USD MILLION)
  • TABLE 352. NATO COMPANION DIAGNOSTICS MARKET SIZE,